Definiens and Bioscan Team Up for Cooperative Marketing Efforts
News Dec 03, 2008
Under the terms of the agreement, Bioscan and Definiens will conduct cooperative marketing activities and host joint workshops and events. Customers will benefit through integrated training and implementation programs and access to the solutions offered by both companies.
Non-invasive in vivo animal imaging offers researchers a window into living biological systems. It provides the means to track a range of biological processes, from metabolism to receptors and gene-expression, and enables the effects of candidate pharmaceutical treatments to be monitored.
Recent improvements in molecular imaging technologies have made in vivo preclinical imaging increasingly important to researchers, and especially to those involved in the drug development process. However, intelligent image analysis is required to extract meaningful insight from the prodigious amounts of data generated by advanced preclinical in vivo imaging systems.
Bioscan develops advanced instrumentation for the detection, synthesis and imaging of radiolabeled compounds used in life science research, molecular imaging, pharmaceutical development and nuclear medicine.
The company’s dual modality NanoSPECT/CT and NanoPET/CT in vivo animal imaging systems provide unparalleled insight into molecular function at the nanoliter level. With these nano-nuclear imagers, Bioscan allows researchers to overcome the challenge of balancing resolution and sensitivity that has hampered the advancement of non-invasive imaging in preclinical studies.
Definiens provides life science organizations with software applications for analyzing and interpreting images on every scale, from cell and tissue-based assays to in-vivo imaging systems.
The company’s proprietary Definiens Cognition Network Technology® is context-based, emulating human cognitive processes to extract intelligence from images of all modalities, sizes, and resolutions. Definiens image analysis software complements Bioscan’s imaging systems, enabling researchers to extract additional quantitative and anatomical information from 3D images of small animal models.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE